Merck KGaA reported second-quarter results that surpassed analysts' forecasts on Thursday, driven by strength in its laboratory equipment and electronics divisions, prompting the company to raise its full-year profit and sales outlook. The German technology and healthcare group now expects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for the year to range between €5.9 billion and €6.3 billion (approximately $6.8 billion to $7.3 billion), up from the previous guidance of €5.7 billion to €6.1 billion. The upper end of its full-year net sales forecast has also been lifted to €21.8 billion, compared to the earlier €21.4 billion target.
The upward revision was attributed to stronger momentum in the life sciences division and the electronics business, as well as easing foreign exchange headwinds. New Chief Executive Officer Kai Beckmann, who took office in May, is focused on driving improvements across the company's three main segments: healthcare, life sciences, and electronics. This marks the second time he has raised the company's guidance since assuming the role. His most significant move to date was the €11.3 billion acquisition of life sciences firm Bio-Techne Corp, announced in June, which represents Merck KGaA's largest deal since the €17 billion purchase of Sigma-Aldrich in 2014. The company has stated that Bio-Techne's lab proteins and instruments will complement its existing portfolio and provide growth drivers post-completion.
In the second quarter, adjusted EBITDA climbed to €1.6 billion, exceeding the average analyst estimate of €1.5 billion compiled by the market. Quarterly sales also surpassed expectations, reaching €5.4 billion. As of Wednesday, Merck KGaA's shares have gained 18% year-to-date, outperforming the largely flat healthcare sector within the Europe Stoxx 600 index.
Breaking down the business segments, the life sciences division, particularly its process solutions unit that supplies pharmaceutical equipment, recorded double-digit growth, continuing a recovery from the post-pandemic inventory destocking cycle. The healthcare segment saw a decline in organic sales for the quarter, weighed down by competitive pressures on its multiple sclerosis drug Mavenclad and oncology treatment Bavencio. Mavenclad faced an adverse patent ruling in the US, allowing generic versions to enter the market earlier than anticipated. However, Merck KGaA stated on Thursday that it now assumes no further sales from the drug starting in August, a delay from the previously assumed May cutoff. Meanwhile, the smallest business segment, electronics, benefited from robust demand for materials used in AI-related chip manufacturing. It is important to note that this company is unrelated to Merck & Co. in the US; although they share a common origin, the two entities have operated independently since World War I.
Comments